Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021 by GBD 2021 Europe Life Expectancy Collaborators (21408850)

Data_Sheet_1_The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for eradicating Helicobacter pylori: a systematic review and meta-analysis of ran... by Yin Chen (125855)

“…Background and objective<p>It remains uncertain if the addition of Saccharomyces boulardii (S. boulardii) to bismuth quadruple therapy (BQT) recommended in the current guidelines can enhance the Helicobacter pylori (H. pylori) eradication rate and decrease the incidence of adverse events. We therefore conducted a meta-analysis of randomized controlled trials (RCTs) to address this issue.…”

Table_2_Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.doc by Jesus D. Melgarejo (11358747)

“…In adjusted mixed models, functional progression of glaucoma damage was associated with VIMmap (−2.57 dB change in MD per every 3 mmHg increase in VIMmap; P < 0.001) and diurnal MAP dips (changes in the MD ranged from −2.56 to −3.19 dB; P < 0.001). Every 5 mmHg decrease in the nocturnal MAP level was associated with −1.14 dB changes in MD [95% confidence interval (CI), −1.90 to −0.40] and 0.01 larger optic disc cupping (95% CI, 0.01–0.02). …”

Table_5_Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.doc by Jesus D. Melgarejo (11358747)

“…In adjusted mixed models, functional progression of glaucoma damage was associated with VIMmap (−2.57 dB change in MD per every 3 mmHg increase in VIMmap; P < 0.001) and diurnal MAP dips (changes in the MD ranged from −2.56 to −3.19 dB; P < 0.001). Every 5 mmHg decrease in the nocturnal MAP level was associated with −1.14 dB changes in MD [95% confidence interval (CI), −1.90 to −0.40] and 0.01 larger optic disc cupping (95% CI, 0.01–0.02). …”

Table_4_Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.doc by Jesus D. Melgarejo (11358747)

“…In adjusted mixed models, functional progression of glaucoma damage was associated with VIMmap (−2.57 dB change in MD per every 3 mmHg increase in VIMmap; P < 0.001) and diurnal MAP dips (changes in the MD ranged from −2.56 to −3.19 dB; P < 0.001). Every 5 mmHg decrease in the nocturnal MAP level was associated with −1.14 dB changes in MD [95% confidence interval (CI), −1.90 to −0.40] and 0.01 larger optic disc cupping (95% CI, 0.01–0.02). …”

Table_3_Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.doc by Jesus D. Melgarejo (11358747)

“…In adjusted mixed models, functional progression of glaucoma damage was associated with VIMmap (−2.57 dB change in MD per every 3 mmHg increase in VIMmap; P < 0.001) and diurnal MAP dips (changes in the MD ranged from −2.56 to −3.19 dB; P < 0.001). Every 5 mmHg decrease in the nocturnal MAP level was associated with −1.14 dB changes in MD [95% confidence interval (CI), −1.90 to −0.40] and 0.01 larger optic disc cupping (95% CI, 0.01–0.02). …”

Table_2_Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.doc by Jesus D. Melgarejo (11358747)

“…In adjusted mixed models, functional progression of glaucoma damage was associated with VIMmap (−2.57 dB change in MD per every 3 mmHg increase in VIMmap; P < 0.001) and diurnal MAP dips (changes in the MD ranged from −2.56 to −3.19 dB; P < 0.001). Every 5 mmHg decrease in the nocturnal MAP level was associated with −1.14 dB changes in MD [95% confidence interval (CI), −1.90 to −0.40] and 0.01 larger optic disc cupping (95% CI, 0.01–0.02). …”

Table_3_Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.doc by Jesus D. Melgarejo (11358747)

“…In adjusted mixed models, functional progression of glaucoma damage was associated with VIMmap (−2.57 dB change in MD per every 3 mmHg increase in VIMmap; P < 0.001) and diurnal MAP dips (changes in the MD ranged from −2.56 to −3.19 dB; P < 0.001). Every 5 mmHg decrease in the nocturnal MAP level was associated with −1.14 dB changes in MD [95% confidence interval (CI), −1.90 to −0.40] and 0.01 larger optic disc cupping (95% CI, 0.01–0.02). …”

Table 2_Inhibitory control in the sober state as a function of alcohol sensitivity: a pilot functional magnetic resonance imaging (fMRI) study.docx by Roberto U. Cofresí (20800094)

“…Based on these preliminary findings, future studies with larger samples are warranted to determine the extent to which domain-general IC performance associated with fronto-cortico-striatal IC circuit activation contributes to the alcohol use pathophysiology, and whether therapeutic interventions (e.g., non-invasive brain stimulation) targeting fronto-cortico-striatal IC circuitry may decrease AUD symptomatology.…”

Table_4_Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.doc by Jesus D. Melgarejo (11358747)

“…In adjusted mixed models, functional progression of glaucoma damage was associated with VIMmap (−2.57 dB change in MD per every 3 mmHg increase in VIMmap; P < 0.001) and diurnal MAP dips (changes in the MD ranged from −2.56 to −3.19 dB; P < 0.001). Every 5 mmHg decrease in the nocturnal MAP level was associated with −1.14 dB changes in MD [95% confidence interval (CI), −1.90 to −0.40] and 0.01 larger optic disc cupping (95% CI, 0.01–0.02). …”

Table_5_Progression of functional and structural glaucomatous damage in relation to diurnal and nocturnal dips in mean arterial pressure.doc by Jesus D. Melgarejo (11358747)

“…In adjusted mixed models, functional progression of glaucoma damage was associated with VIMmap (−2.57 dB change in MD per every 3 mmHg increase in VIMmap; P < 0.001) and diurnal MAP dips (changes in the MD ranged from −2.56 to −3.19 dB; P < 0.001). Every 5 mmHg decrease in the nocturnal MAP level was associated with −1.14 dB changes in MD [95% confidence interval (CI), −1.90 to −0.40] and 0.01 larger optic disc cupping (95% CI, 0.01–0.02). …”

Does Spatial Isolation Confer Market Power? Evidence from the market for retail gasoline by Will Shallcross Peckham (14101428)

“…The magnitude of the effect decreases with the duration of the closure and the station's distance from the nearest exit, and is larger for unbranded stations that might be able to more readily adjust their prices.…”

Differential genome-wide distribution of epigenetic markers between HCV infected vs. non-infected cells and its integration with gene expression. by Shira Perez (6857819)

“…Plots demonstrate an average of three to five biological replicates for each ChIP-seq and six biological replicates for RNA-seq experiment. …”

Image 4_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Data Sheet 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by figshare admin frontiersin (4545187)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Data Sheet 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.pdf by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 2_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 3_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Table 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.xlsx by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”

Image 1_Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study.tiff by Øystein Fluge (200378)

“…DePaul Questionnaire-Short Form (DSQ-SF) symptom scores decreased from 72.3 to 43.1 (p = 0.002). In six responders, mean SF-36 PF increased from 32.2 to 78.3, and DSQ-SF score decreased from 71.1 to 24.3. …”